Sorry, you need to enable JavaScript to visit this website.

Safety Bridge | XARELTO® (rivaroxaban) HCP

XARELTO® safety across 9 indications

XARELTO® has proven safety and efficacy profiles in 9 indications: NVAF, PAD post LER, CAD, PAD, VTE prophylaxis for acute medically ill patients, DVT/PE initial treatment, DVT/PE extended treatment, or DVT prophylaxis after hip or knee surgery. To learn more about the data, please visit the indication-specific safety pages below.

NVAF
SAFETY

PAD POST LER
SAFETY

CAD AND/OR PAD
SAFETY

VTE PROPHYLAXIS
SAFETY

DVT/PE INITIAL TREATMENT
SAFETY

DVT/PE EXTENDED TREATMENT
SAFETY

DVT PROPHYLAXIS
SAFETY

◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

CAD = coronary artery disease; DVT = deep vein thrombosis; LER = lower extremity revascularization; NVAF = nonvalvular atrial fibrillation; PAD = peripheral artery disease; PE = pulmonary embolism; VTE = venous thromboembolism.